-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Gilead Sciences today announced the latest positive results
Patients in the Trodelvy treatment group achieved statistically significant and clinically significant improvements in overall survival (OS) Gilead has filed a Supplemental Biologics Licensing Application (sBLA) with the U.
Trodelvy is a "first-in-class" antibody-conjugated drug
Trodelvy is a "first-in-class" antibody-conjugated drug
The median overall survival of the key secondary endpoints published this time showed that the median overall survival of Trodelvy and the control group was 14.
The median overall survival of Trodelvy and control groups was 14.